151 related articles for article (PubMed ID: 17431671)
1. Predominant expression of OLIG2 over ID2 in oligodendroglial tumors.
Mikami S; Hirose Y; Yoshida K; Kawase T; Ohnishi A; Nagashima K; Mukai M; Okada Y; Ikeda E
Virchows Arch; 2007 May; 450(5):575-84. PubMed ID: 17431671
[TBL] [Abstract][Full Text] [Related]
2. Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors.
Hirose T; Ishizawa K; Shimada S
Neuropathology; 2010 Dec; 30(6):586-96. PubMed ID: 20408960
[TBL] [Abstract][Full Text] [Related]
3. Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas.
Riemenschneider MJ; Koy TH; Reifenberger G
Acta Neuropathol; 2004 Mar; 107(3):277-82. PubMed ID: 14730454
[TBL] [Abstract][Full Text] [Related]
4. Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells.
Bouvier C; Bartoli C; Aguirre-Cruz L; Virard I; Colin C; Fernandez C; Gouvernet J; Figarella-Branger D
J Neurosurg; 2003 Aug; 99(2):344-50. PubMed ID: 12924709
[TBL] [Abstract][Full Text] [Related]
5. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
[TBL] [Abstract][Full Text] [Related]
6. OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms.
Preusser M; Budka H; Rössler K; Hainfellner JA
Histopathology; 2007 Feb; 50(3):365-70. PubMed ID: 17257132
[TBL] [Abstract][Full Text] [Related]
7. Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas.
Bannykh SI; Stolt CC; Kim J; Perry A; Wegner M
J Neurooncol; 2006 Jan; 76(2):115-27. PubMed ID: 16205963
[TBL] [Abstract][Full Text] [Related]
8. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
Rousseau A; Nutt CL; Betensky RA; Iafrate AJ; Han M; Ligon KL; Rowitch DH; Louis DN
J Neuropathol Exp Neurol; 2006 Dec; 65(12):1149-56. PubMed ID: 17146289
[TBL] [Abstract][Full Text] [Related]
9. SOX10 and Olig2 as negative markers for the diagnosis of ependymomas: An immunohistochemical study of 98 glial tumors.
Švajdler M; Rychlý B; Mezencev R; Fröhlichová L; Bednárová A; Pataky F; Daum O
Histol Histopathol; 2016 Jan; 31(1):95-102. PubMed ID: 26287936
[TBL] [Abstract][Full Text] [Related]
10. Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas.
Yokoo H; Nobusawa S; Takebayashi H; Ikenaka K; Isoda K; Kamiya M; Sasaki A; Hirato J; Nakazato Y
Am J Pathol; 2004 May; 164(5):1717-25. PubMed ID: 15111318
[TBL] [Abstract][Full Text] [Related]
11. Id2 mediates oligodendrocyte precursor cell maturation arrest and is tumorigenic in a PDGF-rich microenvironment.
Havrda MC; Paolella BR; Ran C; Jering KS; Wray CM; Sullivan JM; Nailor A; Hitoshi Y; Israel MA
Cancer Res; 2014 Mar; 74(6):1822-32. PubMed ID: 24425046
[TBL] [Abstract][Full Text] [Related]
12. Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
Ishizawa K; Komori T; Shimada S; Hirose T
Clin Neuropathol; 2008; 27(3):118-28. PubMed ID: 18552083
[TBL] [Abstract][Full Text] [Related]
13. Oligodendroglial tumors with marked desmoplasia: clinicopathologic and molecular features of 7 cases.
Jentoft M; Giannini C; Rossi S; Mota R; Jenkins RB; Rodriguez FJ
Am J Surg Pathol; 2011 Jun; 35(6):845-52. PubMed ID: 21552114
[TBL] [Abstract][Full Text] [Related]
14. OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms.
Otero JJ; Rowitch D; Vandenberg S
J Neurooncol; 2011 Sep; 104(2):423-38. PubMed ID: 21193945
[TBL] [Abstract][Full Text] [Related]
15. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification.
Mokhtari K; Paris S; Aguirre-Cruz L; Privat N; Crinière E; Marie Y; Hauw JJ; Kujas M; Rowitch D; Hoang-Xuan K; Delattre JY; Sanson M
Neuropathol Appl Neurobiol; 2005 Feb; 31(1):62-9. PubMed ID: 15634232
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology.
Rhee W; Ray S; Yokoo H; Hoane ME; Lee CC; Mikheev AM; Horner PJ; Rostomily RC
Glia; 2009 Apr; 57(5):510-23. PubMed ID: 18837053
[TBL] [Abstract][Full Text] [Related]
17. A distinct pattern of Olig2-positive cellular distribution in papillary glioneuronal tumors: a manifestation of the oligodendroglial phenotype?
Tanaka Y; Yokoo H; Komori T; Makita Y; Ishizawa T; Hirose T; Ebato M; Shibahara J; Tsukayama C; Shibuya M; Nakazato Y
Acta Neuropathol; 2005 Jul; 110(1):39-47. PubMed ID: 15906048
[TBL] [Abstract][Full Text] [Related]
18. Nogo-A expression in oligodendroglial tumors.
Jung TY; Jung S; Lee KH; Cao VT; Jin SG; Moon KS; Kim IY; Kang SS; Kim HS; Lee MC
Neuropathology; 2011 Feb; 31(1):11-9. PubMed ID: 20487307
[TBL] [Abstract][Full Text] [Related]
19. Expression of the oligodendroglial lineage-associated markers Olig1 and Olig2 in different types of human gliomas.
Ohnishi A; Sawa H; Tsuda M; Sawamura Y; Itoh T; Iwasaki Y; Nagashima K
J Neuropathol Exp Neurol; 2003 Oct; 62(10):1052-9. PubMed ID: 14575240
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic signaling is dominant to cell of origin and dictates astrocytic or oligodendroglial tumor development from oligodendrocyte precursor cells.
Lindberg N; Jiang Y; Xie Y; Bolouri H; Kastemar M; Olofsson T; Holland EC; Uhrbom L
J Neurosci; 2014 Oct; 34(44):14644-51. PubMed ID: 25355217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]